

1632  
8

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Jim McWhir, *et al.*

Serial No.: 09/995,419

Filing Date: November 26, 2001

Attorney Docket: 096/004

For: SELECTIVE ANTIBODY TARGETING OF  
UNDIFFERENTIATED STEM CELLS

Art Unit: 1632

Examiner: Joseph T. Woitach

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Arlington, VA 22313-1450


Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

Authorization to charge Deposit Account 07/1139 with the fee therefore under 37 CFR § 1.117(p) is provided in the accompanying fee transmittal. Should any other fee be required for further consideration of the application, the Commissioner is hereby authorized to charge said fees (or credit any overpayment) to the Deposit Account, referencing the attorney Docket Number indicated above.


Respectfully submitted,



J. Michael Schiff  
Registration No. 40,253

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
Telephone: (650) 473-7715  
Fax: (650) 473-8654

Sept 23, 2004



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$)

180

## Complete if Known

Application Number	09/995,419
Filing Date	November 26, 2001
First Named Inventor	Jim McWhir, et al.
Examiner Name	Joseph T. Woitach
Art Unit	1632
Attorney Docket No.	096/004

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit  
Account  
Number  
Deposit  
Account  
Name

07-1139

Geron Corporation

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)			(\$) 0

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	
Multiple Dependent	-3** =	X	

<u>Large Entity</u>		<u>Small Entity</u>		<u>Fee Description</u>
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180

## SUBMITTED BY

(Complete (if applicable))

Name (Print/Type)	J. Michael Schiff	Registration No. (Attorney/Agent)	40,253	Telephone	(650) 473-7715
Signature		Date	Sept 28/04		

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/995,419	
	Filing Date	November 26, 2001	
	First Named Inventor	Jim McWhir, et al.	
	Art Unit	1632	
	Examiner Name	Joseph T. Voitach	
Total Number of Pages in This Submission	8	Attorney Docket Number	096/004

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form (in duplicate) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (2 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks</b> 1. Form 1449 (3 pages) with copies of 34 references 2. Return receipt postcard		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	J. Michael Schiff, Registration No. 40,253
Signature	
Date	SEP 23/04

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Form 1449 (modified)	Docket: 096/004	U.S.S.N.: 09/995,419
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Title: Selective Antibody Targeting of Undifferentiated Stem Cells	
(Use Several Sheets if Necessary)	Inventors: Jim McWhir, et al.	Group: 1632
	Filing Date: November 26, 2001	

# U.S. PATENT DOCUMENTS

Examiner Initial	Ref.	Document No.	Filing Date	Publication Date	Class/ Subclass	Inventors	Title
none							

# FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Ref.	Document No.	Publication Date	Jurisdiction	Title	Translation
	BA	WO 99/45100	Sep 10/99	PCT	Embryonic or Stem-Like Cell Lines Produced by Cross-Species Nuclear Transplantation	N/A
	BB	WO 00/46355	Aug 10/00	PCT	Telomerase Reverse Transcriptase Regulatory Sequences	N/A
	BC	WO 01/11011	Feb 15/01	PCT	Multipotent Adult Stem Cells and Methods for Isolation	N/A
	BD	WO 01/88104	Nov 22/01	PCT	Neural Progenitor Cell Populations	N/A

# OTHER DOCUMENTS

Examiner Initial	Ref.	Author, Title, Source, Date
	BE	Bradley JA et al, Stem Cell Medicine Encounters the Immune System, Immunology 2:859 (2002)
	BF	Clausen H et al, Carbohydrates of the Cell Surface: Molecular Aspects of Glycosyltransferases and Their Genes, APMIS (Suppl 27) 100:9 (1992)
	BG	Gorelik E et al, On the Role of Cell Surface Carbohydrates and Their Binding Proteins (Lectins) in Tumor Metastasis, Cancer & Metastasis Rev 20:245 (2001)
	BH	Thiem J, Substrate Specificity and Synthetic Use of Glycosyltransferases, Ernst Schering Res Found Workshop 44:75 (2004)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form 1449 (modified)</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use Several Sheets if Necessary)	<b>Docket:</b> 096/004  <b>Title:</b> Selective Antibody Targeting of Undifferentiated Stem Cells <b>Inventors:</b> Jim McWhir, et al.  <b>Filing Date:</b> November 26, 2001	<b>U.S.S.N.:</b> 09/995,419  <b>Group:</b> 1632
---	--	---

OLB  
SEP 28 2004  
PATENT & TRADEMARK OFFICE

**U.S. PATENT DOCUMENTS**

Examiner Initial	Ref.	Document No.	Filing Date	Publication Date	Class/ Subclass	Inventors	Title
none							

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

Examiner Initial	Ref.	Document No.	Publication Date	Jurisdiction	Title	Translation
none						

**OTHER DOCUMENTS**

Examiner Initial	Ref.	Author, Title, Source, Date
	CA	Abuljadayel IS, Induction of Stem Cell-Like Plasticity in Mononuclear Cells Derived from Unmobilised Adult Human Peripheral Blood, Curr Med Res Opin 19(5):355 (2003)
	CB	D'Ippolito G et al, Marrow-Isolated Adult Multilineage Inducible (MIAMI) Cells, a Unique Population of Postnatal Young and Old Human Cells with Extensive Expansion and Differentiation Potential, J Cell Science 117:2971 (2004)
	CC	Dyce PW et al, Stem Cells with Multilineage Potential Derived from Porcine Skin, Biochem Biophys Res Comm 316:651 (2004)
	CD	Forsyth NR et al, Telomerase and Differentiation in Multicellular Organisms: Turn it Off, Turn it On, and Turn it Off Again, Differentiation 69:188 (2002)
	CE	Gammaitoni L et al, Elevated Telomerase Activity and Minimal Telomere Loss in Cord Blood Long-Term Cultures with Extensive Stem Cell Replication, Blood 103(12):4440 (2004)
	CF	Goolsby J et al, Hematopoietic Progenitors Express Neural Genes, PNAS 100(25):14926 (2003)
	CG	Hashimoto N et al, Bone Marrow-Derived Progenitor Cells in Pulmonary Fibrosis, J Clin Invest 113(2):243 (2004)
	CH	Hodes RJ et al, Telomeres in T and B Cells, Nat Rev 2:699 (2002)
	CI	Mattson MP et al, Assessing the Involvement of Telomerase in Stem Cell Biology, Methods Molecular Biol 198:125 (2002)
	CJ	Moore JE et al, The Corneal Epithelial Stem Cell, DNA Cell Biol 21 (5/6):443 (2002)
	CK	Murasawa S et al, Constitutive Human Telomerase Reverse Transcriptase Expression Enhances Regenerative Properties of Endothelial Progenitor Cells, Circulation 106:1133 (2002)
	CL	Oh H et al, Cardiac Muscle Plasticity in Adult and Embryo by Heart-Derived Progenitor Cells, Ann NY Acad Sci 1015:182 (2004)
	CM	Parsch D et al, Telomere Length and Telomerase Activity During Expansion and Differentiation of Human Mesenchymal Stem Cells and Chondrocytes, J Molecular Med, 82(1):49 (2004)
	CN	Planz B et al, Studies on the Differentiation Pathway and Growth Characteristics of Epithelial Culture Cells of the Human Prostate, Prostate Cancer Prostatic Dis 7:73 (2004)
	CO	Pochampally RR et al, Serum Deprivation of Human Marrow Stromal Cells (hMSCs) Selects for a Subpopulation of Early Progenitor Cells with Enhanced Expression of OCT-4 and Other Embryonic Genes, Blood 103(5):1647 (2004)
	CP	Prowse KR, Detection of Telomerase Activity in Neural Cells, Methods Molecular Biol 198:137 (2002)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449 (modified)	Docket: 096/004	U.S.S.N.: 09/995,419
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Title: Selective Antibody Targeting of Undifferentiated Stem Cells Inventors: Jim McWhir, et al.	
(Use Several Sheets if Necessary)	Filing Date: November 26, 2001	Group: 1632



CQ	Reim G et al, The POU Domain Protein Spg (Pou2/Oct4) is Essential for Endoderm Formation in Cooperation with the HMG Domain Protein Casanova, Dev Cell 6:91 (2004)
CR	Rubin H, Promise and Problems in Relating Cellular Senescence in Vitro to Aging in Vivo, Archives Gerontology Geriatrics 34:275 (2002)
CS	Seruya M et al, Clonal Population of Adult Stem Cells: Life Span and Differentiation Potential, Cell Transpl 13:93 (2004)
CT	Swynghedauw B, Are Adult Cardiocytes Still Able to Proliferate?, Archives des Maladies du Coeur et des Vaisseaux 96(12):1225 (2003) (French)
CU	Szyper-Kravitz M et al, Granulocyte Colony-Stimulating Factor Administration Upregulates Telomerase Activity in CD34 <sup>+</sup> Haematopoietic Cells and May Prevent Telomere Attrition After Chemotherapy, Brit J Haematology 120:329 (2003)
CV	Tabilio A et al, Expression of SSEA-I Antigen (3-fucosyl-N-acetyl-lactosamine) on Normal and Leukaemic Human Haematopoietic Cells: Modulation by Neuraminidase Treatment, Brit J Haematology 58:697 (1984)
CW	Tang DG et al, Lack of Replicative Senescence in Cultured Rat Oligodendrocyte Precursor Cells, Science 291:868 (2001)
CX	Tsai MS et al, Isolation of Human Multipotent Mesenchymal Stem Cells from Second-Trimester Amniotic Fluid Using a Novel Two-Stage Culture Protocol, Human Reprod 19(6):1450 (2004)
CY	Villa A et al, Long-Term Molecular and Cellular Stability of Human Neural Stem Cell Lines, Exper Cell Res 294:559 (2004)
CZ	Yui J et al, Telomerase Activity in Candidate Stem Cells from Fetal Liver and Adult Bone Marrow, Blood 91(9):3255 (1998)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.